Eli Lilly makes Mounjaro, the diabetes and weight-management drug whose commercial success helped propel the company’s market value.
Mounjaro is the brand name for tirzepatide when used to improve blood-sugar control in adults with type 2 diabetes. Tirzepatide activates receptors for GIP and GLP-1, two hormones involved in glucose regulation and appetite. The same active ingredient is marketed as Zepbound in the United States for chronic weight management.
Eli Lilly and Company was founded in 1876 by Colonel Eli Lilly, a pharmaceutical chemist and Union army veteran. The company is headquartered in Indianapolis, Indiana, and has developed medicines in areas including diabetes, oncology, immunology, and neuroscience.
Mounjaro and Zepbound are different brand names for tirzepatide and have different approved indications. They should not be confused with semaglutide products such as Ozempic and Wegovy, which are made by Novo Nordisk. Pharmaceutical valuations can change substantially as clinical evidence, approvals, and sales expectations evolve.